• Nature

COVID-19 vigilance

Updated: Dec 7, 2020

Clinical trials of four vaccine candidates are showing remarkable promise, with three exceeding 90% efficacy, no safety concerns and one has shown promise in older adults.

COVAX, a global alliance seeking to ensure that low- and middle-income countries get adequate vaccine provision, has only been able to secure vaccines for around 250 million people — far below what is needed.

Importantly, AstraZeneca and Oxford have pledged to provide their vaccine at cost price to all during the pandemic, and to maintain this price for low- and middle-income countries after the pandemic, when a vaccine will still be needed in case of future outbreaks. As infectious-disease researchers often say, an outbreak anywhere is an outbreak everywhere. Read more ...

Wear a mask, social distance, wash your hands, and get the vaccine (Facebook is now taking down misinformation on vaccines). See IATA to monitor international travel restrictions, and Commonwealth Innovation for Commonwealth country COVID performance.

2 views0 comments

Recent Posts

See All

How should we Mask COVID-19?

Global coronavirus deaths have been falling—but scientists are worried that more infectious new variants of the virus may reverse those trends. As quickly as vaccines were developed, the virus has ev

Happy Holidays - 2020

As we enter the holiday season, the Board of Directors of the Royal Commonwealth Society Ottawa reflects on the year that was 2020. As a registered education charity we: ESTABLISH BURSARIES for Common

How We Can Stop the Spread of COVID-19 By Christmas

We have a long road ahead before a vaccine is safe, effective and, most crucially, widely available. We need a multi-pronged public health strategy that includes a national testing plan that utilizes

RCS Ottawa

Basil Crozier - Chair


© 2020 By Royal Commonwealth Society Ottawa  Charity# 119128916RR0001

established 1968